IRS lengthy case backlog frustrates identity theft victims
Taxpayers waited about 20 months for the IRS to process their identity theft cases in recent years, frustrating and burdening taxpayers expecting tax refunds.
Why advisors are rethinking entity structures for clients — and maybe themselves
Recent tax law changes are prompting businesses to rethink entity structures. Here’s what financial advisors need to know when guiding clients or making decisions about their own RIAs.
GASB offers guidance on financial reporting improvements
The Governmental Accounting Standards Board released an implementation guide with questions and answers clarifying the requirements related to subsidies.
Why autonomous finance won’t be built alone
Every journal entry, reconciliation and audit trail must be accurate, explainable and defensible. AI doesn’t lower that bar; it raises the stakes for meeting it.
IRS sets per diem rates for travelers for 2026-2027
The Internal Revenue Service issued its annual notice setting the daily rates that business travelers can use when deducting their expenses.
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
FDA inspectors found evidence that the compounding pharmacy was making versions of Eli Lilly’s tirzepatide and Novo’s semaglutide “regularly or in inordinate amounts” at a site with “insanitary conditions.”
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward
While Acadia Pharmaceuticals’ candidate has missed the main goal of a Phase 2 trial, the company is still moving forward with the anti-psychosis candidate in Alzheimer’s disease as well as Lewy body dementia.
Backed by NVIDIA and Anthropic, Basecamp bags $140M to advance AI-designed drugs
Basecamp Research joins the growing group of AI-forward biotechs that in recent months have brought in notable sums from investors, including Isomorphic Labs and Enveda.
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
The new partnership follows Roche’s recent R&D expansion in Boston focused on development for cardiovascular, renal and metabolic diseases.
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
InnoCare Pharma is the latest addition to Eli Lilly’s dealmaking spree, which includes some of the biggest acquisitions this year: up to $7 billion for Kelonia Therapeutics in April and up to $7.8 billion for Centessa Pharmaceuticals in March.